GPC3 CAR-T cells were injected via the tail vein into tumor-bearing mice treated with or without AAV-CCL19 for 7 days to further verify whether the better antitumor effect produced by the combination of CAR-T cells and AAV was due to the chemotactic effect of CCL19 on T cells. The gene discussed is CCL19; the disease is neoplasm.